CY1125175T1 - Παραγωγα πολυμυξινης και η χρηση τους σε συνδυασμενη θεραπεια μαζι με διαφορετικα αντιβιοτικα - Google Patents

Παραγωγα πολυμυξινης και η χρηση τους σε συνδυασμενη θεραπεια μαζι με διαφορετικα αντιβιοτικα

Info

Publication number
CY1125175T1
CY1125175T1 CY20221100299T CY221100299T CY1125175T1 CY 1125175 T1 CY1125175 T1 CY 1125175T1 CY 20221100299 T CY20221100299 T CY 20221100299T CY 221100299 T CY221100299 T CY 221100299T CY 1125175 T1 CY1125175 T1 CY 1125175T1
Authority
CY
Cyprus
Prior art keywords
combination therapy
different antibiotics
polymyxin derivatives
iii
compounds
Prior art date
Application number
CY20221100299T
Other languages
Greek (el)
English (en)
Inventor
Pamela Brown
Michael Dawson
Mona SIMONOVIC
Steven Boakes
Esther DUPERCHY
Steven James Stanway
Antoinette Wilson
Stephen Frederick Moss
Original Assignee
Spero Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB201404301A external-priority patent/GB201404301D0/en
Priority claimed from GB201421019A external-priority patent/GB201421019D0/en
Application filed by Spero Therapeutics, Inc. filed Critical Spero Therapeutics, Inc.
Publication of CY1125175T1 publication Critical patent/CY1125175T1/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/60Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation occurring through the 4-amino group of 2,4-diamino-butanoic acid
    • C07K7/62Polymyxins; Related peptides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CY20221100299T 2014-03-11 2022-04-20 Παραγωγα πολυμυξινης και η χρηση τους σε συνδυασμενη θεραπεια μαζι με διαφορετικα αντιβιοτικα CY1125175T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB201404301A GB201404301D0 (en) 2014-03-11 2014-03-11 Compounds and combinations
GB201421019A GB201421019D0 (en) 2014-11-26 2014-11-26 Compounds

Publications (1)

Publication Number Publication Date
CY1125175T1 true CY1125175T1 (el) 2024-12-13

Family

ID=52823596

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20221100299T CY1125175T1 (el) 2014-03-11 2022-04-20 Παραγωγα πολυμυξινης και η χρηση τους σε συνδυασμενη θεραπεια μαζι με διαφορετικα αντιβιοτικα

Country Status (21)

Country Link
US (3) US20170073373A1 (enExample)
EP (1) EP3116897B1 (enExample)
JP (1) JP6785659B2 (enExample)
KR (2) KR20160135739A (enExample)
CN (1) CN106232617B (enExample)
AU (1) AU2015228898B2 (enExample)
CA (1) CA2940455C (enExample)
CY (1) CY1125175T1 (enExample)
DK (1) DK3116897T3 (enExample)
ES (1) ES2910072T3 (enExample)
HR (1) HRP20220387T1 (enExample)
IL (1) IL247243B (enExample)
LT (1) LT3116897T (enExample)
MX (1) MX359104B (enExample)
PL (1) PL3116897T3 (enExample)
PT (1) PT3116897T (enExample)
RS (1) RS63138B1 (enExample)
RU (1) RU2740190C2 (enExample)
SI (1) SI3116897T1 (enExample)
TW (1) TWI709575B (enExample)
WO (1) WO2015135976A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2780357A1 (en) * 2011-11-18 2014-09-24 Novacta Biosystems Limited Polymyxin derivatives
HUE068512T2 (hu) 2014-04-01 2024-12-28 Univ Monash Polimixin-származékok mint antimikrobális vegyületek
AU2015352440B2 (en) 2014-11-26 2020-02-06 Spero Therapeutics, Inc. Compounds
CA2970546A1 (en) 2014-12-16 2016-06-23 Micurx Pharmaceuticals, Inc. Antimicrobial polymyxins for treatment of bacterial infections
CN105030744B (zh) * 2015-07-09 2019-04-19 广州英赛特生物技术有限公司 取代苯胍衍生物作为多粘菌素类抗生素增效剂的应用
EP3356387B1 (en) * 2015-09-29 2024-06-26 Monash University Antimicrobial polymyxin derivative compounds
JP6744622B2 (ja) * 2016-06-16 2020-08-19 学校法人上智学院 ピペリジン化合物の製造方法
WO2019084628A1 (en) * 2017-11-02 2019-05-09 The University Of Queensland Peptide antibiotics
EA202092819A1 (ru) 2018-06-25 2021-05-21 Сперо Терапьютикс, Инк. Соединения
CN111690040A (zh) * 2019-03-12 2020-09-22 上海来益生物药物研究开发中心有限责任公司 多粘菌素衍生物、其制备方法和应用
US20230141981A1 (en) 2020-01-21 2023-05-11 Shanghai Micurx Pharmaceuticals Co., Ltd Novel compounds and composition for targeted therapy of kidney-associated cancers
TW202233649A (zh) 2020-11-06 2022-09-01 美商斯佩羅治療學股份有限公司 化合物
CN120699105B (zh) * 2025-08-19 2025-11-21 中国药科大学 一种氘代抗菌肽及其组合物和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060004185A1 (en) * 2004-07-01 2006-01-05 Leese Richard A Peptide antibiotics and peptide intermediates for their prepartion
EP3078672A1 (en) * 2006-08-11 2016-10-12 Northern Antibiotics Oy Polymyxin derivatives and uses thereof
AR074874A1 (es) * 2008-12-23 2011-02-16 Biosource Pharm Inc Composiciones antibioticas para el tratamiento de infecciones gram negativas. metodo. uso. compuesto.
CN101851270A (zh) * 2009-04-03 2010-10-06 梁浩 一种多粘菌素衍生物及其制备方法
US8415307B1 (en) * 2010-06-23 2013-04-09 Biosource Pharm, Inc. Antibiotic compositions for the treatment of gram negative infections
WO2012168820A1 (en) * 2011-06-08 2012-12-13 Pfizer Inc. Polymyxin derivatives useful as antibacterial agents
EP2780357A1 (en) * 2011-11-18 2014-09-24 Novacta Biosystems Limited Polymyxin derivatives
HUE059544T2 (hu) * 2013-05-22 2022-11-28 Spero Therapeutics Inc Polimixin-származékok és ezek alkalmazása kombinációs terápiában különbözõ antibiotikumokkal

Also Published As

Publication number Publication date
JP2017510570A (ja) 2017-04-13
US20210221848A1 (en) 2021-07-22
DK3116897T3 (da) 2022-03-28
HRP20220387T1 (hr) 2022-05-27
TWI709575B (zh) 2020-11-11
CN106232617A (zh) 2016-12-14
ES2910072T3 (es) 2022-05-11
JP6785659B2 (ja) 2020-11-18
US20170073373A1 (en) 2017-03-16
IL247243B (en) 2020-04-30
PT3116897T (pt) 2022-04-07
AU2015228898B2 (en) 2018-11-15
WO2015135976A1 (en) 2015-09-17
KR20160135739A (ko) 2016-11-28
MX359104B (es) 2018-09-14
EP3116897B1 (en) 2022-03-02
MX2016011682A (es) 2017-04-27
PL3116897T3 (pl) 2022-05-30
CA2940455A1 (en) 2015-09-17
RU2740190C2 (ru) 2021-01-12
KR20230152779A (ko) 2023-11-03
TW201617362A (zh) 2016-05-16
AU2015228898A1 (en) 2016-10-20
US20230322858A1 (en) 2023-10-12
SI3116897T1 (sl) 2022-06-30
RU2016139978A3 (enExample) 2018-10-17
RU2016139978A (ru) 2018-04-13
CA2940455C (en) 2023-03-21
CN106232617B (zh) 2022-06-24
IL247243A0 (en) 2016-09-29
LT3116897T (lt) 2022-05-10
RS63138B1 (sr) 2022-05-31
EP3116897A1 (en) 2017-01-18

Similar Documents

Publication Publication Date Title
CY1125175T1 (el) Παραγωγα πολυμυξινης και η χρηση τους σε συνδυασμενη θεραπεια μαζι με διαφορετικα αντιβιοτικα
CY1123598T1 (el) Μακροκυκλικα πεπτιδια χρησιμα ως ανοσοδιαμορφωτες
CL2019001874A1 (es) Inhibidores de tgfß1 isoforma-específicos contexto-permisivos y uso de los mismos.
CY1122065T1 (el) Ενωσεις αλκυλ-αμιδο-υποκατεστημενου πυριδυλιου χρησιμες ως διαμορφωτες των αποκρισεων il-12, il-23 και/η ιfναλφα
CY1121701T1 (el) Οργανικες ενωσεις μονοβακταμης για την αντιμετωπιση βακτηριακων λοιμωξεων
HUE057426T2 (hu) Heteroaril-szubsztituált béta-hidroxietilamin-származékok magas vécukorszint kezelésére való alkalmazásra
CL2016002027A1 (es) Ciclopropilamina como inhibidor de la lsd1
CY1121384T1 (el) Συνδυαστικη θεραπεια για την αγωγη ανθεκτικων βακτηριακων λοιμωξεων
MX2020002823A (es) Fluorofenil beta-hidroxietilaminas y su uso en el tratamiento de la hiperglucemia.
CY1122805T1 (el) Ενωσεις και μεθοδοι για την αγωγη βακτηριακων λοιμωξεων
GT201500088A (es) Derivados de 5-fenoxi-3h-pirimidin-4-ona y su uso como inhibidores de la transcriptasa inversa del vih
UY34657A (es) ?derivados macrocíclicos para el tratamiento de enfermedades?.
UY34278A (es) Derivados novedosos de oxazina y su uso en el tratamiento de enfermedades
CY1120607T1 (el) Παραγωγα ισοϊνδολινης για χρηση στη θεραπεια μιας ιικης μολυνσης
CY1122818T1 (el) Παραγωγα 3-((ετερο-)αρυλ)-αλκυλ-8-αμινο-2-οξο-1,3-διαζα- σπε1ρο-[4.5]-δεκανιου
MX381911B (es) Derivados heterociclicos y uso de los mismos.
CY1116186T1 (el) Μακροκυκλικες ενωσεις και μεθοδοι για την παραγωγη τους
IL271863B (en) Compounds and use thereof for the treatment of microbial infections
CY1122923T1 (el) Παραγωγα 3-((ετερο-)αρυλ)-8-αμινο-2-οξο-1,3-διαζα-σπειρο-[4.5]-δεκανιου
CL2015003019A1 (es) Derivados biaromáticos antibacterianos
CY1122882T1 (el) Παραγωγα 3-(καρβοξυαιθυλ)-8-αμινο-2-οξο-1,3-διαζα-σπειρο-[4.5]-δεκανιου
BR112017026061A2 (pt) composto, uso de um composto, e, método de tratamento de uma infecção viral
CY1122971T1 (el) Ενωσεις διυδροπυριμιδιν-2-ονης και ιaτρικη χρηση αυτων
EA201691412A1 (ru) Гидроксиформамидные производные и их применение
MX391999B (es) Piridinas y su uso en el tratamiento del cáncer.